Pharmacogenetic Biomarkers of Ibrutinib Response and Toxicity in Chronic Lymphocytic Leukemia: Insights from an Observational Study

Pharmacogenetic Biomarkers of Ibrutinib Response and Toxicity in Chronic Lymphocytic Leukemia: Insights from an Observational Study

<b>Background/Objectives:</b> Ibrutinib is a selective Bruton’s tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL). This drug exhibits significant variability in response and toxicity profile, possibly due to genetic polymorphisms in drug-metaboliz...

Full description

Saved in:
Bibliographic Details
Main Authors: Noelia Pérez-Gómez, Antonio Sanz-Solas, Beatriz Cuevas, María Victoria Cuevas, Cristina Alonso-Madrigal, Javier Loscertales, Rodolfo Álvarez-Nuño, Covadonga García, Pablo Zubiaur, Gonzalo Villapalos-García, Raúl Miguel Parra-Garcés, Gina Mejía-Abril, Raquel Alcaraz, Raquel Vinuesa, Francisco Javier Díaz-Gálvez, María González-Oter, Natalia García-Sancha, Raúl Azibeiro-Melchor, Tomás José González-López, Francisco Abad-Santos, Jorge Labrador, Miriam Saiz-Rodríguez
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Pharmaceuticals
Subjects:
chronic lymphocytic leukemia
ibrutinib
pharmacogenetics
polymorphisms
Online Access:https://www.mdpi.com/1424-8247/18/7/996
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1424-8247/18/7/996

Similar Items